|
1
|
Mardiros A, Brown CE, Budde LE, Wang X and
Forman SJ: Acute myeloid leukemia therapeutics: CARs in the
driver’s seat. Oncoimmunology. 12:e272142013. View Article : Google Scholar
|
|
2
|
Joshi I, Yoshida T, Jena N, Qi X, Zhang J,
Van Etten RA and Georgopoulos K: Loss of Ikaros DNA-binding
function confers integrin-dependent survival on pre-B cells and
progression to acute lymphoblastic leukemia. Nat Immunol.
15:294–304. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rashid A, Lee NG, Jakobiec FA and Freitag
SK: Epstein-Barr virus-positive polymorphous lymphoplasmacytic
infiltrate of the lacrimal glands in a patient with acute
lymphoblastic leukemia. JAMA Ophthalmol. 132:892–894. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yuasa M, Ishiwata K, Sugio T, et al:
Herpes simplex virus type 2 fulminant hepatitis after umbilical
cord blood transplantation for acute myeloid leukemia. Rinsho
Ketsueki. 55:682–686. 2014.(In Japanese). PubMed/NCBI
|
|
5
|
Shamroe CL and Comeau JM: Ponatinib: A new
tyrosine kinase inhibitor for the treatment of chronic myeloid
leukemia and Philadelphia chromosome-positive acute lymphoblastic
leukemia. Ann Pharmacother. 11:1540–1546. 2013. View Article : Google Scholar
|
|
6
|
Badura S, Tesanovic T, Pfeifer H, Wystub
S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M and
Ottmann OG: Differential effects of selective inhibitors targeting
the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. PLoS
One. 11:e800702013. View Article : Google Scholar
|
|
7
|
Han SS, Han S and Kamberos NL:
Piperlongumine inhibits the proliferation and survival of B-cell
acute lymphoblastic leukemia cell lines irrespective of
glucocorticoid resistance. Biochem Biophys Res Commun. 452:669–675.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pei S, Minhajuddin M, Callahan KP, et al:
Targeting aberrant glutathione metabolism to eradicate human acute
myelogenous leukemia cells. J Biol Chem. 288:33542–33558. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Makhov P, Golovine K, Teper E, Kutikov A,
Mehrazin R, Corcoran A, Tulin A, Uzzo RG and Kolenko VM:
Piperlongumine promotes autophagy via inhibition of Akt/mTOR
signalling and mediates cancer cell death. Br J Cancer.
110:899–907. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ginzburg S, Golovine KV, Makhov PB, Uzzo
RG, Kutikov A and Kolenko VM: Piperlongumine inhibits NF-κB
activity and attenuates aggressive growth characteristics of
prostate cancer cells. Prostate. 2:177–186. 2014. View Article : Google Scholar
|
|
11
|
Liu Y, Chang Y, Yang C, et al:
Biodegradable nanoassemblies of piperlongumine display enhanced
anti-angiogenesis and anti-tumor activities. Nanoscale.
6:4325–4337. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vasconcelos FC, Nestal de Moraes G,
Moellmann-Coelho A and Maia RC: Phosphorylated Crkl reduction
levels are associated with the lowest P-glycoprotein activity
levels in cells from chronic myeloid leukemia patients. Leuk Res.
12:1711–1718. 2013. View Article : Google Scholar
|
|
13
|
Doroshow JH: Overcoming resistance to
targeted anticancer drugs. N Engl J Med. 19:1852–1853. 2013.
View Article : Google Scholar
|
|
14
|
Ariës IM, Hansen BR, Koch T, van den
Dungen R, Evans WE, Pieters R and den Boer ML: The synergism of
MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell
survival and prednisolone resistance. Haematologica. 12:1905–1911.
2013. View Article : Google Scholar
|
|
15
|
Daflon-Yunes N, Pinto-Silva FE, Vidal RS,
Novis BF, Berguetti T, Lopes RR, Polycarpo C and Rumjanek VM:
Characterization of a multidrug-resistant chronic myeloid leukemia
cell line presenting multiple resistance mechanisms. Mol Cell
Biochem. 1–2:123–135. 2013. View Article : Google Scholar
|
|
16
|
Wang JY, Yu P, Chen S, Xing H, Chen Y,
Wang M, Tang K, Tian Z, Rao Q and Wang J: Activation of Rac1 GTPase
promotes leukemia cell chemotherapy resistance, quiescence and
niche interaction. Mol Oncol. 5:907–916. 2013. View Article : Google Scholar
|
|
17
|
Karami H, Baradaran B, Esfahani A, Estiar
MA, Naghavi-Behzad M, Sakhinia M and Sakhinia E: siRNA-mediated
silencing of survivin inhibits proliferation and enhances etoposide
chemosensitivity in acute myeloid leukemia cells. Asian Pac J
Cancer Prev. 12:7719–7724. 2013. View Article : Google Scholar
|
|
18
|
Shi X, Chen X, Li X, Lan X, Zhao C, Liu S,
Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou
QP and Liu J: Gambogic acid induces apoptosis in imatinib-resistant
chronic myeloid leukemia cells via inducing proteasome inhibition
and caspase-dependent Bcr-Abl downregulation. Clin Cancer Res.
1:151–163. 2014. View Article : Google Scholar
|
|
19
|
Chromik J, Safferthal C, Serve H and Fulda
S: Smac mimetic primes apoptosis-resistant acute myeloid leukaemia
cells for cytarabine-induced cell death by triggering necroptosis.
Cancer Lett. 1:101–109. 2014. View Article : Google Scholar
|
|
20
|
Rahgozar S, Moafi A, Abedi M,
Entezar-E-Ghaem M, Moshtaghian J, Ghaedi K, Esmaeili A and
Montazeri F: mRNA expression profile of multidrug-resistant genes
in acute lymphoblastic leukemia of children, a prognostic value for
ABCA3 and ABCA2. Cancer Biol Ther. 1:35–41. 2014. View Article : Google Scholar
|
|
21
|
Ma H, Cheng L, Hao K, Li Y, Song X, Zhou H
and Jia L: Reversal effect of ST6GAL 1 on multidrug resistance in
human leukemia by regulating the PI3K/Akt pathway and the
expression of P-gp and MRP1. PLoS One. 1:e851132014. View Article : Google Scholar
|
|
22
|
Shrivastava S, Kulkarni P, Thummuri D,
Jeengar MK, Naidu VG, Alvala M, Redddy GB and Ramakrishna S:
Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR
signaling axis to induce caspase-dependent apoptosis in human
triple-negative breast cancer cells. Apoptosis. 7:1148–1164. 2014.
View Article : Google Scholar
|
|
23
|
Liu Z, Zhang YY, Zhang QW, Zhao SR, Wu CZ,
Cheng X, Jiang CC, Jiang ZW and Liu H: 3-Bromopyruvate induces
apoptosis in breast cancer cells by downregulating Mcl-1 through
the PI3K/Akt signaling pathway. Anticancer Drugs. 4:447–455. 2014.
View Article : Google Scholar
|
|
24
|
Reikvam H, Tamburini J, Skrede S, Holdhus
R, Poulain L, Ersvaer E, Hatfield KJ and Bruserud Ø: Antileukaemic
effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene
expression profiles reveal CDC25B expression as determinate of
pharmacological effect. Br J Haematol. 2:200–211. 2014. View Article : Google Scholar
|
|
25
|
Kim MS, Kim GM, Choi YJ, Kim HJ, Kim YJ
and Jin W: TrkC promotes survival and growth of leukemia cells
through Akt-mTOR-dependent up-regulation of PLK-1 and Twist-1. Mol
Cells. 2:177–184. 2013. View Article : Google Scholar
|
|
26
|
Pede V, Rombout A, Vermeire J, Naessens E,
Vanderstraeten H, Philippé J and Verhasselt B: Expression of ZAP70
in chronic lymphocytic leukaemia activates NF-κB signalling. Br J
Haematol. 5:621–630. 2013. View Article : Google Scholar
|
